- Home
- STRO vs SLP Comparison
STRO vs SLP Comparison
Compare STRO & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | SLP |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.1M | 371.9M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | STRO | SLP |
|---|---|---|
| Price | $20.07 | $18.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $31.33 | $24.00 |
| AVG Volume (30 Days) | ★ 257.1K | 162.9K |
| Earning Date | 05-11-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | $38,419,000.00 | ★ $59,577,000.00 |
| Revenue This Year | N/A | $3.80 |
| Revenue Next Year | N/A | $5.90 |
| P/E Ratio | ★ N/A | $42.90 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $0.72 | $11.09 |
| 52 Week High | $43.85 | $21.01 |
Technical Indicators
Market Signals| Indicator | STRO | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 66.07 |
| Support Level | $18.74 | $18.22 |
| Resistance Level | $26.35 | $18.57 |
| Average True Range (ATR) | 1.39 | 0.03 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 25.94 | 87.50 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.